37 results
6-K
EX-99.4
AMYT
Amryt Pharma Plc
12 Apr 23
Current report (foreign)
5:28pm
can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved … . The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status
6-K
EX-99.4
AMYT
Amryt Pharma Plc
31 Mar 22
Results of General Meeting
8:41am
lipodystrophy patient community to raise awareness and highlight the burden and impact of this profoundly distressing condition on lipodystrophy patients … the global lipodystrophy patient community today on World Lipodystrophy Day.”
About Amryt
Amryt is a global commercial-stage biopharmaceutical
6-K
EX-99.1
AMYT
Amryt Pharma Plc
3 Nov 20
Current report (foreign)
8:45am
the Executive Director of debra of America, the only national not - for - profit providing all - inclusive support to the EB community . He currently … . To this end DEBRA has established the EB Community Care Programme to create a high standard of support in the home and community . Good also looks like finding
6-K
EX-99.6
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
in greatest need. We are proud to support the global acromegaly community on Acromegaly Awareness Day 2022.”
About AmrytAmryt is a global commercial
6-K
EX-99.1
AMYT
Amryt Pharma Plc
28 Feb 22
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA
12:00pm
options and the EB community is desperate for a therapy. The EASE study was the largest randomized clinical trial ever conducted in this disease
424B3
sc2pb lxyzq5yy72
28 Feb 22
Prospectus supplement
12:02pm
424B3
6iv wj3tz0o4ldsclnw
28 Feb 22
Prospectus supplement
12:01pm
6-K
EX-99.5
hyh4umepj zndp6q
3 Nov 22
Current report (foreign)
7:44am
6-K
EX-99.2
kcm91 qo93z2
13 Sep 21
Current report (foreign)
8:48am
6-K
EX-99.1
vasptgqreag
20 Jan 21
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6:30am
424B3
f5njv
31 Mar 22
Prospectus supplement
8:44am
424B3
tdh nv5aewxg66tc0f
31 Mar 22
Prospectus supplement
8:44am
6-K
EX-99.1
81qqn2ae4 bj7ipq6
9 Sep 20
Amryt Announces Positive Top Line Results from Pivotal Phase 3 “Ease” Trial of Filsuvez(r) In Epidermolysis Bullosa
8:23am
6-K
EX-99.7
m1y9 1z6vq
3 Nov 22
Current report (foreign)
7:44am
F-1/A
9m66t8jiltl8ik33n tk
12 Jan 21
Registration statement (foreign) (amended)
12:00am
F-1
c8z finhcj
8 Jan 21
Registration statement (foreign)
4:58pm
424B4
0zx59fj gxh
14 Jan 21
Prospectus supplement with pricing info
9:30am
DRS
6dwpo3s5xtyx
18 Dec 20
Draft registration statement
12:00am
DRS
cilc8s7esxv5r
19 Feb 20
Draft registration statement
12:00am
DRS/A
eb1i2h4s5kvy
29 May 20
Draft registration statement (amended)
12:00am